CYP2C0, VKORC1 and CYP4F2 Variant Frequencies in Patients on either Low or High Stable Warfarin Maintenance Therapy in the Ghanaian Population

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Unknown venue

• Publication date

  2014-03-01

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Supplementary Figure 2

  2014influential reference
• PS3-4: Genetic Risk Factors for Major Bleeding in Warfarin Patients in a Community Setting

  2013influential reference
• Prevalence of CYP2C9 and VKORC1 alleles in the Argentine population and implications for prescribing dosages of anticoagulants.

  2012influential reference
• Population and Evolutionary Genetics

  2012cited by this paper
• Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population.

  2011influential reference
• Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients.

  2011cited by this paper
• Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing

  2011cited by this paper
• The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement.

  2011cited by this paper
• Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.

  2010influential reference
• Genetic Factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) Are Predictor Variables for Warfarin Response in Very Elderly, Frail Inpatients

  2010cited by this paper
• The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population

  2010cited by this paper
• Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans

  2010cited by this paper
• The pharmacogenetics of warfarin in clinical practice

  2010cited by this paper
• Genetic and clinical factors relating to warfarin dosing.

  2009cited by this paper
• The largest prospective warfarin-treated cohort supports genetic forecasting.

  2009cited by this paper
• CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.

  2009cited by this paper
• Relative Impact of Genotype and Enzyme Induction on the Metabolic Capacity of CYP2C9 in Healthy Volunteers

  2009cited by this paper
• Rapid single-nucleotide polymorphism detection of cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2.

  2009cited by this paper
• Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population

  2009cited by this paper
• Estimation of the warfarin dose with clinical and pharmacogenetic data.

  2009cited by this paper
• Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients

  2009cited by this paper
• An algorithm for managing warfarin resistance

  2009cited by this paper
• CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M Variant

  2009cited by this paper
• Genetic determinants of response to warfarin during initial anticoagulation.

  2008influential reference
• Pharmacogenomics of 4-Hydroxycoumarin Anticoagulants

  2008cited by this paper
• Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues

  2008cited by this paper
• Genetic Determinants of Response to Warfarin During Initial Anticoagulation

  2008cited by this paper
• Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.

  2008cited by this paper
• Linkage disequilibrium mapping of a breast cancer susceptibility locus near RAI/PPP1R13L/iASPP

  2008cited by this paper
• Cytochrome p450 and chemical toxicology.

  2008cited by this paper
• The Role of Pharmacogenetics in the Metabolism of Antiepileptic Drugs

  2007cited by this paper
• Evaluation of Genetic Factors for Warfarin Dose Prediction

  2007cited by this paper
• Effect of patient-specific factors on weekly warfarin dose

  2007cited by this paper
• Thompson & Thompson Genetics in Medicine

  2007cited by this paper
• Pharmacogenetics of warfarin: current status and future challenges

  2007cited by this paper
• Association of warfarin dose with genes involved in its action and metabolism

  2006cited by this paper
• The pharmocogenomics of warfarin: closing in on personalized medicine.

  2006cited by this paper
• Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

  2006influential reference
• Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population

  2006cited by this paper
• The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension.

  2005cited by this paper
• Systematic overview of warfarin and its drug and food interactions.

  2005cited by this paper
• Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population.

  2005cited by this paper
• Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

  2005cited by this paper
• Several‐fold increase in risk of overanticoagulation by CYP2C9 mutations

  2005cited by this paper
• Warfarin maintenance dosages in the very elderly.

  2005cited by this paper
• Common VKORC1 and GGCX polymorphisms associated with warfarin dose

  2005cited by this paper
• Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations.

  2005cited by this paper
• The pharmacogenetics of coumarin therapy.

  2005cited by this paper
• A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

  2005cited by this paper
• The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cited by this paper
• Identification of the gene for vitamin K epoxide reductase

  2004cited by this paper
• Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.

  2004cited by this paper
• Detection of large-scale variation in the human genome

  2004cited by this paper
• Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin

  2004cited by this paper
• Will tomorrow's medicines work for everyone?

  2004cited by this paper
• Pharmacogenetics – five decades of therapeutic lessons from genetic diversity

  2004cited by this paper
• Large-Scale Copy Number Polymorphism in the Human Genome

  2004cited by this paper
• Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting

  2004cited by this paper
• Pharmacogenetics of oral anticoagulants.

  2003cited by this paper
• Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

  2003cited by this paper
• Inheritance and drug response.

  2003cited by this paper
• Cytochrome P450 enzyme polymorphisms and adverse drug reactions.

  2003cited by this paper
• Clinical relevance of genetic polymorphisms in the human CYP2C9 gene

  2003cited by this paper
• Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population

  2003cited by this paper
• Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin

  2003cited by this paper
• Race, ancestry, and genes: implications for defining disease risk.

  2003cited by this paper
• Practical tips for warfarin dosing and monitoring.

  2003cited by this paper
• Frequency of Cytochrome P450 2C9 (CYP2C9) Alleles in Three Ethnic Groups in Malaysia

  2003cited by this paper
• Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population.

  2002cited by this paper
• CYP2C9 allelic variants: ethnic distribution and functional significance.

  2002cited by this paper
• Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

  2002influential reference
• Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.

  2002cited by this paper
• Pharmacogenetics and personalised medicine

  2002cited by this paper
• Population genetic structure of variable drug response

  2001cited by this paper
• Molecular basis of ethnic differences in drug disposition and response.

  2001influential reference
• Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

  2001cited by this paper
• Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

  2001cited by this paper
• Induction of CYP2C genes in human hepatocytes in primary culture.

  2001cited by this paper
• Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations.

  2001cited by this paper
• Pharmacogenomics, ethnicity, and susceptibility genes

  2001cited by this paper
• Frequency of cytochrome P450 2C9 mutant alleles in a Korean population.

  2001cited by this paper
• MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity.

  2001cited by this paper
• Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.

  2001cited by this paper
• A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients.

  2000cited by this paper
• Response to Warfarin and Other Oral Anticoagulants: Effects of Disease States

  2000cited by this paper
• Pharmacogenomics: translating functional genomics into rational therapeutics.

  1999cited by this paper
• Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist?

  1999cited by this paper
• Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0

  1999cited by this paper
• Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.

  1999cited by this paper
• Population and Evolutionary Genetics

  1999cited by this paper
• Biased tests of association: comparisons of allele frequencies when departing from Hardy-Weinberg proportions.

  1999cited by this paper
• Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

  1998cited by this paper
• A new regimen for starting warfarin therapy in out-patients.

  1998cited by this paper
• Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

  1998influential reference
• Monitoring Adverse Drug Events: The Food and Drug Administration MedWatch Reporting System

  1998cited by this paper
• Human P450 metabolism of warfarin.

  1997influential reference
• Genetic analysis of CYP2C9 polymorphism in a Japanese population.

  1997cited by this paper
• The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase.

  1997cited by this paper
• MedGuide: at last a long-sought opportunity for patient education about prescription drugs.

  1997influential reference
• Introduction: Changing view of sulfation and the cytosolic sulfotransferases

  1997cited by this paper

• PHARMACOGENETIQUE DE L’ACENOCOUMAROL : LES GENES IMPLIQUES DANS LA VARIABILITE DE LA REPONSE ET PROPOSITION D’UN ALGORITHME PREDICTIF DE LA DOSE POUR LA POPULATION MAROCAINE

  2019cites this paper
• The effect of GGCX and CYP4F2 gene polymorphisms in genotype-guided dosing of warfarin in patients with a history of cardiac surgery

  2017cites this paper